o2h

CardiaTec is a digital biotechnology company focused on revolutionizing cardiovascular drug discovery through the integration of artificial intelligence and specialized expertise. The company aims to transform the understanding of cardiovascular disease by developing AI-driven platforms for target identification and novel drug discovery. This approach seeks to provide effective therapeutics for cardiovascular diseases, addressing significant gaps in diagnostics, patient stratification, and treatment options for conditions such as coronary artery disease. By leveraging advanced technology and scientific knowledge, CardiaTec is dedicated to improving healthcare outcomes related to cardiovascular health.

Spirea Ltd. operates as a healthcare technology company that has developed a smart polymer platform for the controlled delivery of drug combinations to maximise the clinical impact of medicines.

Oxford Drug Design focuses on developing innovative therapies to combat drug-resistant infections through advanced drug discovery techniques. The company employs a multidisciplinary research approach that integrates computational chemistry, cheminformatics, mathematics, and cloud computing to enhance the drug discovery process. Its flagship platform, DrugFinder, utilizes cutting-edge technologies to facilitate computer-aided drug discovery, covering all stages from target identification to preclinical studies. By addressing high unmet medical needs, Oxford Drug Design aims to provide healthcare professionals with effective new antibiotics for treating challenging diseases, including cancer and other conditions associated with drug resistance.

Sanome is focused on the development of innovative diagnostic products that utilize various biomarkers for early disease detection and prevention. By combining artificial intelligence with biophysical indicators, the company aims to create engaging and accurate in vitro diagnostic (IVD) tools. These tools are designed to facilitate novel at-home testing solutions, making healthcare more accessible to a broader population. Additionally, Sanome's predictive analytics platform offers clinical insights that support healthcare decision-making, enabling providers to identify potential health issues before they escalate. This approach not only enhances patient outcomes but also improves the overall efficiency of healthcare delivery.

Kuano Ltd provides quantum and AI solutions for molecular designs. It designs inhibitors to combine quantum simulation and machine learning approaches to create effective inhibitors based on the mechanisms of the target enzyme. It designs and selects modules in various sectors, including pharma, crop protection, and industrial chemistry. The company was incorporated in 2020 and is based in London, United Kingdom.

PhoreMost Limited, a drug discovery company, engages in identifying new druggable targets for cancer and other unmet diseases. It develops Site-Seeker, a platform that systematically unmasks druggable sites in the human genome and links them to useful therapeutic functions in a live-cell context. The company was incorporated in 2014 and is based in Cambridge, United Kingdom.

Spirea Ltd. operates as a healthcare technology company that has developed a smart polymer platform for the controlled delivery of drug combinations to maximise the clinical impact of medicines.

Turbine Ltd is a biotechnology company based in Budapest, Hungary, founded in 2015. It specializes in the development of computational models that predict biological and clinical outcomes to aid in cancer drug development. Utilizing its proprietary Simulated Cell technology alongside artificial intelligence, Turbine focuses on understanding the intricate mechanisms of cancer. This approach facilitates the discovery of novel protein targets and precision biomarkers, enhancing the translation of research to patient care. The company also creates cancer combination therapies that clarify the underlying biology of diseases and personalize treatment options. By leveraging bioinformatics and network medicine, Turbine effectively simulates complex interventions, allowing for the screening of numerous drug combinations on simulated cells. This innovative process aims to provide cancer patients with low-cost and effective treatment plans.

Qkine Ltd, founded in 2016 and based in Cambridge, United Kingdom, specializes in the manufacturing of high-purity, animal-derived component-free (ADCF) growth factors and cytokines. The company emerged from Cambridge University and focuses on providing proteins for stem cell growth, differentiation, and regenerative medicine applications. Utilizing advanced protein engineering and optimized production platforms, Qkine addresses supply chain challenges in stem cell science by delivering novel, animal-free proteins. Their products support life science research, particularly in stem cell and organoid culture, enabling scientists to advance their work with high-quality, bioactive proteins.

Pencil Biosciences aims to develop a novel, programmable genome-modulation tool that overcomes the challenges associated with the technologies currently available.

Neurofenix develops an innovative upper limb rehabilitation device aimed at enhancing the recovery process for stroke survivors. This device incorporates a hand-training controller that allows users to engage in video game-based exercises, making rehabilitation both enjoyable and effective. By combining therapy with entertainment, Neurofenix enables stroke victims to perform essential arm and hand rehabilitation exercises in clinical settings or from the comfort of their homes. The company's mission is to make rehabilitation more autonomous and accessible, ultimately improving the quality of life for individuals affected by strokes.

Turbine Ltd is a biotechnology company based in Budapest, Hungary, founded in 2015. It specializes in the development of computational models that predict biological and clinical outcomes to aid in cancer drug development. Utilizing its proprietary Simulated Cell technology alongside artificial intelligence, Turbine focuses on understanding the intricate mechanisms of cancer. This approach facilitates the discovery of novel protein targets and precision biomarkers, enhancing the translation of research to patient care. The company also creates cancer combination therapies that clarify the underlying biology of diseases and personalize treatment options. By leveraging bioinformatics and network medicine, Turbine effectively simulates complex interventions, allowing for the screening of numerous drug combinations on simulated cells. This innovative process aims to provide cancer patients with low-cost and effective treatment plans.

Oxford Drug Design focuses on developing innovative therapies to combat drug-resistant infections through advanced drug discovery techniques. The company employs a multidisciplinary research approach that integrates computational chemistry, cheminformatics, mathematics, and cloud computing to enhance the drug discovery process. Its flagship platform, DrugFinder, utilizes cutting-edge technologies to facilitate computer-aided drug discovery, covering all stages from target identification to preclinical studies. By addressing high unmet medical needs, Oxford Drug Design aims to provide healthcare professionals with effective new antibiotics for treating challenging diseases, including cancer and other conditions associated with drug resistance.

Metrion Biosciences Ltd is a contract research organization specializing in preclinical drug discovery services. Founded in 2015 and based in Cambridge, United Kingdom, the company offers a comprehensive range of services that include ion channel screening, cardiac safety profiling, and neuroscience assays. Metrion provides flexible business models tailored to the needs of its clients, which encompass both fee-for-service and collaborative options. The company is equipped with advanced electrophysiology screening capabilities to support medicinal chemistry optimization programs and integrated drug discovery efforts, ensuring high-quality and compliant preclinical testing.

DeepMatter Group is a big data and analysis company based in Bristol, United Kingdom, that specializes in the digitization of chemistry. The company operates two segments: DeepMatter and InfoChem. Its flagship platform, DigitalGlassware, is designed to enhance reproducibility in chemistry and facilitate the development of optimized chemicals, materials, and formulations across various sectors such as pharmaceutical research, fine chemicals, and education. DeepMatter Group also develops cheminformatics software that manages chemical structures and reactions, providing tools for synthesis planning and reaction prediction. Additionally, the company is involved in the automatic extraction of scientific information from text and images, contributing to the broader goal of chemical discovery. Established in 2006 and formerly known as Cronin Group, DeepMatter Group continues to innovate in the field of chemistry, aiming for advancements like the autonomous synthesis engine, Chemputer.

Exonate Limited is a private biotech company based in Duxford, United Kingdom, specializing in the discovery and development of small molecule drugs aimed at modulating alternative messenger RNA splicing for ophthalmological applications. Founded in 2013, the company emerged from the University of Nottingham and is focused on addressing retinal vascular diseases, particularly diabetic macular oedema (DMO) and wet age-related macular degeneration (wAMD). Exonate's lead program utilizes small molecule inhibitors that selectively target serine/threonine-protein kinase 1 to inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) splice variants. This innovative approach aims to improve therapeutic outcomes and offers a potential alternative to current treatment methods, such as anti-VEGF injections and laser surgery. With a preclinical candidate drug already nominated, Exonate is advancing its research through regulatory toxicology and safety pharmacology studies to facilitate clinical evaluation. The company is backed by an experienced management team with expertise in medicine and drug development.

Stemnovate Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. It specializes in providing innovative tools and technologies for drug screening and safety testing. The company offers a range of products, including induced pluripotent stem cells, primary human and multispecies cells, and a comprehensive cell culture and analysis package. Stemnovate's project, "Liver on chip," focuses on liver toxicity testing and incorporates advanced techniques in cellular reprogramming and organ-on-chip technology. The company also provides services such as cell reprogramming, differentiation, and application development. Its clientele includes pharmacists, contract research organizations, small to medium enterprises, and academic institutions, enabling researchers to overcome challenges associated with traditional mammalian cell lines in drug discovery.

Absynth Biologics Limited focuses on discovering and developing vaccines and therapeutic antibodies aimed at preventing and treating bacterial infections. The company targets significant pathogens, including Staphylococcus aureus, Clostridium difficile, and Streptococcus pyogenes, using a novel platform that identifies protein antigen targets. This approach leverages the immune system through a dual-action mechanism, which includes direct antibacterial effects from antibody-mediated inhibition and the activation of immune effector functions to eliminate bacteria. Founded in 2007 and based in Alderley Edge, United Kingdom, Absynth Biologics is dedicated to advancing immunological prophylaxis and therapy to combat bacterial infections.